PUBLISHER: The Business Research Company | PRODUCT CODE: 1938756
PUBLISHER: The Business Research Company | PRODUCT CODE: 1938756
A veterinary vaccine is a biological preparation designed to stimulate the immune response of an animal, aiming to reduce animal suffering, prevent the transmission of microorganisms within the animal population, and enhance the immune strength of animals for improved health. Additionally, veterinary vaccines play a crucial role in preventing the transmission of diseases from animals to humans.
Various types of veterinary vaccines include live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other vaccine variants. Inactivated vaccines, distinct from live attenuated vaccines, consist of dead or inactivated viruses and bacteria. The diseases targeted by these vaccines encompass anaplasmosis, canine parvovirus, foot and mouth disease, Newcastle disease, distemper disease, influenza, and porcine reproductive and respiratory syndrome. The application areas for veterinary vaccines extend to both livestock vaccines and companion animal vaccines.
Tariffs have impacted the veterinary vaccines market by increasing costs for imported vaccines, biological raw materials, and cold-chain equipment, particularly affecting asia-pacific and european regions with high reliance on imports. This has influenced procurement and pricing for livestock and companion animal vaccines. On the positive side, tariffs have encouraged local vaccine production and innovation, leading to development of cost-effective alternatives and strengthening regional supply chains for long-term market resilience.
The veterinary vaccines market research report is one of a series of new reports from The Business Research Company that provides veterinary vaccines market statistics, including veterinary vaccines industry global market size, regional shares, competitors with a veterinary vaccines market share, detailed veterinary vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary vaccines industry. This veterinary vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The veterinary vaccines market size has grown strongly in recent years. It will grow from $12.54 billion in 2025 to $13.28 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increasing prevalence of animal diseases, rising livestock population, growth in companion animals, government regulations supporting vaccination, advancements in vaccine research and production.
The veterinary vaccines market size is expected to see strong growth in the next few years. It will grow to $16.79 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to emerging biopharmaceutical vaccine technologies, rising demand for preventive veterinary care, adoption of dna and recombinant vaccines, expansion of vaccination programs in emerging markets, increasing awareness of zoonotic disease prevention. Major trends in the forecast period include development of novel livestock vaccines, growth in companion animal vaccination programs, expansion of recombinant and toxoid vaccines, adoption of multi-disease combination vaccines, focus on preventing zoonotic disease transmission.
The rising number of animals affected by various diseases is expected to drive the growth of the veterinary vaccine market in the coming years. Animals suffering from multiple diseases refers to non-human animals experiencing concurrent or sequential pathological conditions, resulting in compounded physical, psychological, and functional harm that severely affects their welfare. This increase is largely due to poor sanitation and hygiene in animal habitats. Veterinary vaccines support these animals by stimulating their immune systems to prevent infections, reduce disease severity, limit transmission, and improve overall health and welfare. For example, in July 2025, according to the UK Health Security Agency, a UK-based government organization, 154 confirmed and probable leptospirosis cases (a bacterial zoonotic infection) were reported in 2024, marking an 11.6% increase from 138 cases in 2023. Therefore, the growing number of animals affected by multiple diseases is propelling the veterinary vaccine market.
Key players in the veterinary vaccine market are developing new products to maintain a competitive edge. These new products include advanced, disease-specific vaccines with improved formulations, broader pathogen coverage, and enhanced safety and efficacy profiles. For instance, in June 2023, Merck Animal Health, a US-based pharmaceutical company, launched Circumvent CML, a three-in-one swine vaccine. This vaccine protects against Porcine Circovirus Type 2a (PCV-2a), Porcine Circovirus Type 2d (PCV-2d), Mycoplasma hyopneumoniae, and Lawsonia intracellularis. By combining multiple antigens and adjuvant systems in a single bottle, it reduces the required dosage and is administered as a single intramuscular injection to pigs aged three weeks or older, simplifying vaccination and reducing stress for both animals and caretakers.
In April 2024, Virbac SA, a France-based provider of animal health products and services, including pharmaceuticals, vaccines, and preventive care solutions for companion and farm animals, acquired Sasaeah Pharmaceutical Co. Ltd. for an undisclosed amount. Through this acquisition, Virbac aimed to strengthen its presence in the Asia Pacific animal health market and enhance its vaccine and pharmaceutical portfolio, particularly in farm animal segments, by integrating Sasaeah's established manufacturing, R&D capabilities, and strong regional distribution network. Sasaeah Pharmaceutical Co. Ltd., based in Japan, develops, manufactures, and markets a broad range of veterinary pharmaceutical products and vaccines for major species, including cattle and other farm animals, supported by facilities in Japan and Vietnam.
Major companies operating in the veterinary vaccines market are Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Elanco Animal Health Incorporated, Ceva Sante Animale., Virbac Group, HIPRA, Biogenesis Bago, Kyoritsu Seiyaku Corporation, Phibro Animal Health Corporation, Century Vaccines Limited, Bayer Animal Health, Cadila Vaccines Ltd., Cargill India Pvt. Ltd., China Animal Healthcare Ltd., Jurox Pty Ltd, Nimrod Veterinary Products Ltd., Bimeda, Animalcare, MSD Animal Health, Interfeed, Biotex Plus Ltd., Belfarmacom, IDT Biologika, UCBVET, Lemavet, Syntec, Sauvet, Vetanco, Chemo Argentina, Brouwer, Agrovet Market Animal Health, DBK Pharma S.A.E.
North America was the largest region in the veterinary vaccines market in 2025. Asia-Pacific was the second-largest region in the global veterinary vaccines market analysis. The regions covered in the veterinary vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the veterinary vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The veterinary vaccines market consists of sales of messenger RNA vaccine, viral vector vaccine, and subunit vaccine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Veterinary Vaccines Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses veterinary vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for veterinary vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The veterinary vaccines market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.